TY - THES A1 - Drehmann, Paul T1 - SLC7A10 als neues Gen für humane Hyperekplexie T1 - SLC7A10 - a novel candidate gene for human hyperekplexia N2 - Neuste Studien haben ergeben, dass Asc-1 Knock-out Mäuse aufgrund einer verminderten intrazellulären Glycinkonzentration in synaptischen Boutons im Gehirn, einen Hyperekplexie-ähnlichen Phänotyp entwickeln. Aufgrund nicht vollständig geklärter Ursachen für die Entstehung des Krankheitsbildes der Hyperekplexie beim Menschen, wurde eine Kohorte von 51 Patienten zusammengetragen, um vor dem Hintergrund der Forschungsergebnisse zu Asc-1 im Tiermodell, das kodierende Gen beim Menschen SLC7A10 als mögliches Kandidatengen auf Sequenzalterationen zu untersuchen. Hierfür wurde aus Vollblut der an Hyperekplexie erkrankten Patienten genomische DNA isoliert, um mittels PCR und anschließendem Screening der Sequenzen, Mutationen innerhalb funktionell wichtiger Bereiche des Gens zu eruieren. Neben weiteren Sequenzunterschieden, die meist in Introns gefunden wurden, wurde die codierende Mutation G307R innerhalb von Exon 7 identifiziert, die letztendlich der Grund für eine Versuchsreihe war, um zu hinterfragen, ob dieser Aminosäureaustausch in der Proteinsequenz funktionelle Konsequenzen zur Folge hat. HEK293-Zellen wurden mit dem zuvor hergestellten Klon G307R transfiziert, um über Biotinylierung, immuncytochemische Färbungen und funktionelle Untersuchungen die Aktivität des Transporters zu beurteilen. Hier zeigte sich ein Funktionsverlust von über 95 %, bei uneingeschränkter Oberflächenexpression. ASC-1 bestätigt sich damit als neue Ursache in der Ausprägung von Hyperekplexie. Ferner können Zusammenhänge mit geistiger Retardierung und eingeschränkter neuronaler Plastizität bestehen. N2 - Recent studies have shown that Asc-1 knock-out mice leads to reduced intracellular glycine concentration in synaptic boutons in the brain followed by a development of a hyperekplexia-like phenotype. In humans, the underlying cause for hyperekplexia is not complexly understood. Based on findings in the Asc-1 knockout mouse model, a patient cohort of 51 patients was used to identify possible sequence alterations in the corresponding Gen SLC7A10 as a novel candidate gene for human hyperekplexia. For this purpose, genomic DNA was extracted from blood samples of patients suffering from hyperekplexia to identify mutations within functionally important areas of the gene by means of PCR and subsequent analyses of the determined sequences. Besides other sequence alterations mainly in introns, the coding mutation G307R within exon 7 was identified and used to investigate functional consequences of this amino acid exchange in an experimental series. The clone ACS-1 G307R was transfected into HEK293 cells to assess the activity of the transporter via biotinylation, immunocytochemical stainings, and functional uptake assays. Our results showed an almost loss of function with more than 95 % reduction in the transport activity although surface expression was unaffected. In conclusion, the ASC-1 mutation was confirmed as a novel cause for human hyperekplexia. In addition, mental retardation and restricted neuronal plasticity might play a role during disease manifestation. KW - Knockout KW - Glycin KW - Aminosäuren KW - Nervenzelle KW - SLC7A10 KW - Hyperekplexie KW - ASC-1 Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-159736 ER - TY - JOUR A1 - Drehmann, Paul A1 - Milanos, Sinem A1 - Schaefer, Natascha A1 - Kasaragod, Vikram Babu A1 - Herterich, Sarah A1 - Holzbach-Eberle, Ulrike A1 - Harvey, Robert J. A1 - Villmann, Carmen T1 - Dual role of dysfunctional Asc-1 transporter in distinct human pathologies, human startle disease, and developmental delay JF - eNeuro N2 - Human startle disease is associated with mutations in distinct genes encoding glycine receptors, transporters or interacting proteins at glycinergic synapses in spinal cord and brainstem. However, a significant number of diagnosed patients does not carry a mutation in the common genes GLRA1, GLRB, and SLC6A5. Recently, studies on solute carrier 7 subfamily 10 (SLC7A10; Asc-1, alanine-serine-cysteine transporter) knock-out (KO) mice displaying a startle disease-like phenotype hypothesized that this transporter might represent a novel candidate for human startle disease. Here, we screened 51 patients from our patient cohort negative for the common genes and found three exonic (one missense, two synonymous), seven intronic, and single nucleotide changes in the 5′ and 3′ untranslated regions (UTRs) in Asc-1. The identified missense mutation Asc-1\(^{G307R}\) from a patient with startle disease and developmental delay was investigated in functional studies. At the molecular level, the mutation Asc-1\(^{G307R}\) did not interfere with cell-surface expression, but disrupted glycine uptake. Substitution of glycine at position 307 to other amino acids, e.g., to alanine or tryptophan did not affect trafficking or glycine transport. By contrast, G307K disrupted glycine transport similar to the G307R mutation found in the patient. Structurally, the disrupted function in variants carrying positively charged residues can be explained by local structural rearrangements because of the large positively charged side chain. Thus, our data suggest that SLC7A10 may represent a rare but novel gene associated with human startle disease and developmental delay. KW - Asc-1 transporter KW - candidate gene KW - glycine receptor KW - glycine uptake KW - human startle disease KW - NMDAR Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-349947 VL - 10 IS - 11 ER -